Macquarie maintains outperform on Jubilant Life Sciences
Macquarie has maintained its "outperform" rating on Jubilant Life Sciences for a target of Rs 725. Free-cash flow generation is the key to stock performance. Scale-up in speciality business will lead to margin sustenance. Recent financial discipline is a key positive for the company.